State Street’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.69M | Buy |
76,633
+3,631
| +5% | +$161K | ﹤0.01% | 3076 |
|
|
2025
Q4 | $3.01M | Sell |
73,002
-2,048
| -3% | -$82.2K | ﹤0.01% | 3201 |
|
|
2025
Q3 | $2.91M | Buy |
75,050
+2,146
| +3% | +$69.7K | ﹤0.01% | 3214 |
|
|
2025
Q2 | $2.02M | Sell |
72,904
-635,905
| -90% | -$16.2M | ﹤0.01% | 3312 |
|
|
2025
Q1 | $15.7M | Sell |
708,809
-20,770
| -3% | -$428K | ﹤0.01% | 2268 |
|
|
2024
Q4 | $14.4M | Buy |
729,579
+24,867
| +4% | +$568K | ﹤0.01% | 2415 |
|
|
2024
Q3 | $17.6M | Sell |
704,712
-713,235
| -50% | -$17.4M | ﹤0.01% | 2285 |
|
|
2024
Q2 | $26.5M | Sell |
1,417,947
-470,597
| -25% | -$8.82M | ﹤0.01% | 2024 |
|
|
2024
Q1 | $37.3M | Buy |
1,888,544
+342,448
| +22% | +$6.69M | ﹤0.01% | 1876 |
|
|
2023
Q4 | $27.1M | Sell |
1,546,096
-215,576
| -12% | -$3.54M | ﹤0.01% | 2036 |
|
|
2023
Q3 | $30.6M | Buy |
1,761,672
+109,701
| +7% | +$1.85M | ﹤0.01% | 1910 |
|
|
2023
Q2 | $23.3M | Sell |
1,651,971
-145,473
| -8% | -$1.95M | ﹤0.01% | 2158 |
|
|
2023
Q1 | $19.3M | Buy |
1,797,444
+307,333
| +21% | +$4.05M | ﹤0.01% | 2251 |
|
|
2022
Q4 | $22.3M | Buy |
1,490,111
+878,769
| +144% | +$12.8M | ﹤0.01% | 2167 |
|
|
2022
Q3 | $7.85M | Buy |
611,342
+26,511
| +5% | +$302K | ﹤0.01% | 2844 |
|
|
2022
Q2 | $5.67M | Buy |
584,831
+17,693
| +3% | +$165K | ﹤0.01% | 3045 |
|
|
2022
Q1 | $5.64M | Sell |
567,138
-898,033
| -61% | -$9.51M | ﹤0.01% | 3120 |
|
|
2021
Q4 | $17.2M | Sell |
1,465,171
-568,911
| -28% | -$6.99M | ﹤0.01% | 2573 |
|
|
2021
Q3 | $23.2M | Sell |
2,034,082
-260,622
| -11% | -$3.39M | ﹤0.01% | 2376 |
|
|
2021
Q2 | $32M | Buy |
2,294,704
+879,922
| +62% | +$13.4M | ﹤0.01% | 2180 |
|
|
2021
Q1 | $26.2M | Sell |
1,414,782
-163,730
| -10% | -$3.35M | ﹤0.01% | 2189 |
|
|
2020
Q4 | $27.9M | Buy |
1,578,512
+1,164,059
| +281% | +$20.4M | ﹤0.01% | 2022 |
|
|
2020
Q3 | $6.35M | Buy |
414,453
+90,573
| +28% | +$1.7M | ﹤0.01% | 2670 |
|
|
2020
Q2 | $8.25M | Buy |
323,880
+100,650
| +45% | +$2.1M | ﹤0.01% | 2528 |
|
|
2020
Q1 | $3.46M | Sell |
223,230
-2,002
| -0.9% | -$31.3K | ﹤0.01% | 2806 |
|
|
2019
Q4 | $2.49M | Sell |
225,232
-4,245
| -2% | -$36.9K | ﹤0.01% | 3169 |
|
|
2019
Q3 | $1.95M | Buy |
229,477
+9,282
| +4% | +$103K | ﹤0.01% | 3227 |
|
|
2019
Q2 | $2.98M | Buy |
220,195
+93,972
| +74% | +$1.46M | ﹤0.01% | 3070 |
|
|
2019
Q1 | $2.28M | Buy |
126,223
+44,499
| +54% | +$860K | ﹤0.01% | 3108 |
|
|
2018
Q4 | $2.3M | Buy |
81,724
+17,225
| +27% | +$359K | ﹤0.01% | 3062 |
|
|
2018
Q3 | $1.65M | Buy |
+64,499
| New | +$1.25M | ﹤0.01% | 3317 |
|
Other funds holding KNSA
RCMNY
BBA
TCM
VPM
VCM
State Street's KNSA Position: Q1 2026 in Review
State Street increased its Kiniksa Pharmaceuticals (KNSA) stake by 5% in Q1 2026, buying an estimated $161K and bringing the position to 76,633 shares worth $3.69M. The position accounts for ﹤0.01% of the portfolio, ranked #3076.
State Street first reported a position in KNSA in Q3 2018 and has held it in 31 quarters since. The position peaked at $37.3M in Q1 2024. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.
- State Street held 76,633 shares of Kiniksa Pharmaceuticals worth $3.69M as of Q1 2026.
- State Street bought 3,631 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $161K.
- Kiniksa Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3076 holding.
- State Street first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
- State Street's Kiniksa Pharmaceuticals position peaked at $37.3M in Q1 2024.
- 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.